The pharma index has hugely underperformed the Sensex in CY17 owing to regulatory overhang and FDA issues
Nilesh Shetty and Anand Shah on whether pharma stocks can make a comeback
Over the past three years, the NSE Pharma Index has fallen 30% even as the benchmark Nifty rose 18%
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Despite the strong industry headwind, Torrent Pharma remains in the pink of health, thanks to its diversified geographical presence and specialty products
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
With a powerful client base and an all-in-one package, the contract R&D firm Syngene is galloping ahead and now even into manufacturing
Edelweiss Securities' head of research sees huge potential in Dr Reddy's, and also an attractive valuation
Investors worry about poor corporate governance practices at Sun Pharma and price erosion in the US generics market
By riding business and earning cycles, Invesco’s Amit Ganatra’s stock bets have paid rich dividend
As the market tumbles, mutual fund managers recommend pharma, private banks and specialty chemicals to tide over the volatility
The pharma industry has to deal with poor road connectivity and an unskilled labour force in Sikkim, but it seems to have made peace with the mountains
Here is a list of stocks that have fallen in the small and mid-cap carnage despite reporting robust numbers
Laurus Lab founder Satyanarayana Chava increases stake as the stock loses steam post its weak show in Q4FY18
The worst seems to be behind for Sun Pharma as its Halol plant seems set for clearance and its specialty portfolio tests water in the US
By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next
When change sets in, companies initially live in denial, and when it catches up, it’s too late
Laurus Labs is crucially poised, as investors look forward to its R&D efforts finally paying off
After emerging as the global leader in the oral care segment, Essel Propack is betting on the non-oral space to sustain its growth momentum
Secret Diary of Ajay Piramal — Part 2
Secret Diary of Ajay Piramal — Part 3
